|1.||Maslov, L N: 11 articles (09/2014 - 05/2001)|
|2.||Krylatov, A V: 10 articles (09/2014 - 06/2001)|
|3.||Lasukova, O V: 6 articles (01/2012 - 09/2003)|
|4.||Mechoulam, R: 5 articles (11/2012 - 11/2000)|
|5.||Pertwee, R G: 5 articles (07/2007 - 06/2001)|
|6.||Vaughan, Christopher W: 4 articles (01/2008 - 07/2005)|
|7.||Mitchell, Vanessa A: 4 articles (01/2008 - 07/2005)|
|8.||Lishmanov, Iu B: 3 articles (01/2012 - 05/2001)|
|9.||Ermakov, S Iu: 3 articles (07/2008 - 04/2006)|
|10.||Crawford, D: 3 articles (07/2008 - 04/2006)|
|1.||Brain Injuries (Brain Injury)
01/01/2006 - "We sought to assess the safety and efficacy of dexanabinol, a synthetic cannabinoid analogue devoid of psychotropic activity, in severe traumatic brain injury. "
01/01/2006 - "Dexanabinol is safe, but is not efficacious in the treatment of traumatic brain injury."
01/01/2006 - "Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial."
03/01/2002 - "Dexanabinol as a treatment for traumatic brain injury: will another therapeutic promise be broken?"
01/01/2003 - "Dexanabinol (HU-211), a synthetic cannabinoid, is currently being assessed in clinical trials for traumatic brain injury and stroke. "
|2.||Neuralgia (Stump Neuralgia)
12/01/2001 - "The aim of the present study was to investigate the effect of a potent cannabinoid agonist, HU210, on somatosensory transmission in a model of neuropathic pain. "
02/01/2006 - "In the present study, we compared the effect of a selective FAAH inhibitor, URB597, to that of a pan-cannabinoid receptor agonist HU210 in rat models of chronic inflammatory and neuropathic pain. "
02/01/2006 - "In contrast, HU210, but not URB597, reduced mechanical allodynia in the partial sciatic nerve-ligation model of neuropathic pain. "
05/01/2001 - "In the partial sciatic ligation model of neuropathic pain WIN55,212-2, CP-55,940 and HU-210 produced complete reversal of mechanical hyperalgesia within 3 h of subcutaneous administration with D50 values of 0.52, 0.08 and 0.005 mg kg(-1), respectively. "
07/15/2005 - "In the present study we found that systemic administration of the cannabinoid acid derivative 1',1'-dimethylheptyl-delta-8-tetrahydrocannabinol-11-oic acid (ajulemic acid, IP-751) and the non-selective cannabinoid receptor agonist HU-210 reduced mechanical allodynia in a nerve-injury induced model of neuropathic pain and in the CFA-induced model of inflammatory pain. "
02/01/1995 - "These results suggest that the synthetic cannabinoid HU-210 acts in the preoptic area, probably via the brain cannabinoid receptor to induce hypothermia. "
01/01/2003 - "Four therapeutic strategies appear to be the most promising approaches currently in clinical trials for severe traumatic brain injury: a) the novel pharmacologic agent dexanabinol; b) hypertonic saline; c) mild hypothermia; and d) decompressive craniectomy. "
11/01/2003 - "New therapies currently under investigation include the use of dexanabinol, hypertonic saline solutions, moderate hypothermia, decompressive craniectomy, optimization of cerebral perfusion pressure, and reduction in cerebral microvasculature pressure (Lund therapy). "
05/01/2001 - "WIN55,212-2 (0.3-10 mg kg(-1)), CP-55,940 (0.03-1 mg kg(-1)) and HU-210 (0.001-0.03 mg kg(-1)) were all active in a 'tetrad' of tests consisting of tail-flick, catalepsy, rotarod and hypothermia following subcutaneous administration, with a rank order of potency in each of HU-210 > CP-55,940 > WIN55,212-2. "
02/01/1995 - "Intracerebral administration of IL-1 or PGE2 to rats pretreated with HU-210 caused a transient inhibition of the hypothermia. "
01/03/2000 - "The results suggest that dexanabinol may provide an alternative mode of treatment for acute exacerbations of multiple sclerosis (MS)."
01/03/2000 - "Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis."
01/01/2003 - "Dexanabinol is in clinical trials for traumatic brain injury (head injuries), glaucoma and mild cognitive impairment, and is being investigated preclinically for its potential in the treatment of multiple sclerosis. "
01/01/2007 - "Psychoactive and nonpsychoactive cannabinoid-based drugs such as Delta9-tetrahydrocannabinol, cannabidiol, HU-211, and ajulemic acid have been tested and found moderately effective in clinical trials of multiple sclerosis, traumatic brain injury, arthritis, and neuropathic pain. "
12/01/2000 - "Dexanabinol is a non-psychotropic cannabinoid NMDA receptor antagonist under development by Pharmos Corp for the potential treatment of cerebral ischemia, glaucoma, Alzheimer's disease, cardiac failure, head injury and multiple sclerosis (MS) ; it is in phase III trials for traumatic brain injury (TBI) . "
|5.||Brain Ischemia (Cerebral Ischemia)
01/01/1994 - "The novel tricyclic-terpenoid type cannabinoid, HU-211, was tested in gerbils and rats for protection against the effects of cerebral ischemia. "
05/18/2001 - "Long term cerebroprotective effects of dexanabinol in a model of focal cerebral ischemia."
01/15/1999 - "Dexanabinol; a novel neuroprotective drug in experimental focal cerebral ischemia."
12/01/1995 - "These results demonstrate the neuroprotective ability of HU-211 in focal cerebral ischemia as judged by neurological score, infarct size, and brain swelling. "
08/01/2003 - "Combination of dexanabinol and tempol in focal cerebral ischemia: is there a ceiling effect?"
|1.||Cannabinoid Receptors (Cannabinoid Receptor)
|3.||CB1 Cannabinoid Receptor (CB1 Receptor)
|6.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|8.||Win 55212-2 (WIN 55,212)
|9.||Levodopa (L Dopa)